# OnCo record drug-discovery-roadmap (roadmap). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/roadmaps/drug-discovery-roadmap/>
  a schema:CreativeWork ;
  onco:kind "roadmap" ;
  schema:identifier "drug-discovery-roadmap" ;
  schema:name "Drug discovery roadmap: screening in mice → maps of dependency → designing in silico"@en ;
  schema:description "Finding the next cancer drug used to mean testing compounds on mice and cell lines and hoping. It now means mapping which genes each cancer cannot live without, growing a patient's tumour in a dish, and designing molecules on a computer; the job is making those tools predict what happens in people."@en ;
  schema:url <https://onco.cc/roadmaps/drug-discovery-roadmap/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://depmap.org/portal/>, <https://doi.org/10.1038/s41586-024-07487-w>, <https://www.tahoebio.ai/> ;
  onco:related <https://onco.cc/collections/depmap/>, <https://onco.cc/collections/cancer-models/>, <https://onco.cc/collections/tcga-gdc/>, <https://onco.cc/collections/genie/>, <https://onco.cc/collections/cptac/>, <https://onco.cc/collections/tahoe-100m/>, <https://onco.cc/collections/arc-virtual-cell-atlas/>, <https://onco.cc/roadmaps/virtual-cell/>, <https://onco.cc/roadmaps/ai-oncology-roadmap/>, <https://onco.cc/roadmaps/adc-generations/>, <https://onco.cc/ideas/idea-tr2-organoid-coclinical-arms/>, <https://onco.cc/ideas/idea-tr2-reference-model-panels/>, <https://onco.cc/ideas/idea-bio1-in-silico-trials-dose/>, <https://onco.cc/ideas/idea-bio1-multi-organ-chip-tox/>, <https://onco.cc/ideas/idea-tr2-phd-replication-year/>, <https://onco.cc/ideas/idea-tr2-preclinical-negative-registry/>, <https://onco.cc/ideas/idea-bio2-shared-compound-access-pool/>, <https://onco.cc/ideas/idea-bio1-undruggable-market-commitment/> ;
  onco:sections <https://onco.cc/fronts/drug-discovery/> ;
  onco:technologies <https://onco.cc/technologies/crispr-screens/>, <https://onco.cc/technologies/organoids/>, <https://onco.cc/technologies/pdx-models/>, <https://onco.cc/technologies/functional-drug-testing/>, <https://onco.cc/technologies/organoid-guided-therapy-scale/>, <https://onco.cc/technologies/pdac-organoid-pharmacotyping/>, <https://onco.cc/technologies/bh3-profiling/>, <https://onco.cc/technologies/high-throughput-screening-libraries/>, <https://onco.cc/technologies/structural-biology-infrastructure/>, <https://onco.cc/technologies/ai-drug-design/>, <https://onco.cc/technologies/de-novo-protein-design/>, <https://onco.cc/technologies/alphafold3/>, <https://onco.cc/technologies/boltz/>, <https://onco.cc/technologies/chai-1/>, <https://onco.cc/technologies/rfdiffusion/>, <https://onco.cc/technologies/esm3/>, <https://onco.cc/technologies/chemistry42/>, <https://onco.cc/technologies/phenom-2/>, <https://onco.cc/technologies/protac-degrader/>, <https://onco.cc/technologies/molecular-glue-platforms/>, <https://onco.cc/technologies/peptide-drug-conjugate/>, <https://onco.cc/technologies/antisense-sirna/>, <https://onco.cc/technologies/degrader-antibody-conjugate/>, <https://onco.cc/technologies/synthetic-lethality-approaches/>, <https://onco.cc/technologies/proteomics/>, <https://onco.cc/technologies/geneformer/>, <https://onco.cc/technologies/scgpt/>, <https://onco.cc/technologies/state-arc/>, <https://onco.cc/technologies/digital-twins-trials/> ;
  onco:drugs <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/dactinomycin/>, <https://onco.cc/drugs/imatinib/>, <https://onco.cc/drugs/sotorasib/> ;
  onco:companies <https://onco.cc/companies/isomorphic-labs/>, <https://onco.cc/companies/insilico-medicine/>, <https://onco.cc/companies/recursion/>, <https://onco.cc/companies/exscientia/>, <https://onco.cc/companies/xaira-therapeutics/>, <https://onco.cc/companies/generate-biomedicines/>, <https://onco.cc/companies/chai-discovery/>, <https://onco.cc/companies/hub-organoids/>, <https://onco.cc/companies/champions-oncology/>, <https://onco.cc/companies/sengine/>, <https://onco.cc/companies/curesponse/>, <https://onco.cc/companies/araris/>, <https://onco.cc/companies/bicycle-therapeutics/>, <https://onco.cc/companies/frontier-medicines/>, <https://onco.cc/companies/vevo-therapeutics/>, <https://onco.cc/companies/google-deepmind/> ;
  onco:institutions <https://onco.cc/institutions/nci/>, <https://onco.cc/institutions/arc-institute/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-preclinical-models/>, <https://onco.cc/bottlenecks/b-reproducibility/>, <https://onco.cc/bottlenecks/b-translational-valley/>, <https://onco.cc/bottlenecks/b-undruggable-targets/>, <https://onco.cc/bottlenecks/b-ip-collaboration/>, <https://onco.cc/bottlenecks/b-negative-results/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-abramson-nature/> .